K. Ray-Chaudhuri, MD, DSc, FRCP, FEAN, King’s College London, London, UK, shares an update on two clinical trials exploring the addition of opicapone to levodopa to address non-motor symptoms. The randomized, double-blind placebo-controlled OCEAN study (OpiCapone Effect on motor fluctuations and pAiN; NCT04986982) investigating opicapone for modulating pain in Parkinson’s disease is currently recruiting, and results are eagerly awaited. The OASIS study (OpicApone Sleep dISorder; NCT04986995) will evaluate the effects of opicapone on sleep disorders in Parkinson’s disease patients. This interview took place at the 2022 International Congress of Parkinson’s Disease and Movement Disorders in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.